Clinical TrialsMedicare | Clinical TrialsPrivate Insurance | Medicare Payment FDA | Cancer Research | Stem Cell Research | Privacy | Other |
||||
CLC
URGES BROAD COVERAGE OF COLORECTAL CANCER
AND OTHER ANTI-CANCER DRUGS (December 23, 2004)
December 23, 2004 Submitted by Mail
Re: Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2005 [CMS-1429-FC] To Whom It May Concern: As organizations involved in cancer treatment, research and patient advocacy, we commend the Centers for Medicare & Medicaid Services (CMS), and you personally, for the recent announcement of a one-year demonstration project to assess quality care for Medicare patients undergoing chemotherapy. This project provides important near-term support for necessary provider services associated with delivery of cancer chemotherapy, but also establishes a foundation for longer term assessment of the needs of cancer patients and the best means of addressing those needs. In this major new
initiative, we applaud your willingness to consult with thought leaders
in the provider and patient communities to assure that the assessment
tools are most appropriate to the circumstances. A year's worth of well-designed
data collection will represent a significant first step toward the sort
of information collection that is required to measure quality cancer care,
but we would hope that CMS also would be open to extension of the one-year
project beyond 2005 in order to move toward a permanent information gathering
system. In addition, there may be other information elements that should
be collected and assessed for future applications, including, for example,
potential coding and reimbursement for chemotherapy management of oral
anticancer agents that are increasingly an integral part of modern cancer
care. Sincerely,
Back to Medicare Payment Index About
CLC | What's New |
Policy Issues |
Participants' Login Copyright
© 2001-2002 Cancer Leadership Council. All rights reserved. |
||||